<DOC>
	<DOC>NCT02997189</DOC>
	<brief_summary>This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.</brief_summary>
	<brief_title>Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Subject is aged 6 months to 21 years inclusive. Subject is diagnosed with neuroblastoma, hepatoblastoma, osteosarcoma or extracranial germ cell tumors and has not been previously treated with cisplatin or carboplatin. Subject is scheduled to receive a chemotherapy regimen that includes a cumulative cisplatin dose of ≥ 200 mg/m2. Subject has normal baseline auditory function, defined as ≤ 20 dB from 2000 to 8000 Hz, in both ears and does not have a history of sensorineural hearing loss. Subject has middle ear effusion upon clinical examination. Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study. Subject is receiving sodiumthiosulfate or amifostine therapy with chemotherapy. Subject is currently participating on a separate otoprotection clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>